Tocilizumab in MOG-antibody spectrum disorder: a case report.

[1]  K. Fujihara,et al.  CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  Jacqueline Palace,et al.  MOG encephalomyelitis: international recommendations on diagnosis and antibody testing , 2018, Journal of Neuroinflammation.

[3]  S. Vukusic,et al.  Neuromyelitis optica and neuromyelitis optica spectrum disorders , 2017, Current opinion in neurology.

[4]  H. Hartung,et al.  Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. , 2015, JAMA neurology.

[5]  S. Kusunoki,et al.  Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica , 2014, Neurology.

[6]  F. Paul,et al.  Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS) , 2013, Journal of Neurology.

[7]  R. Gold,et al.  Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. , 2013, JAMA neurology.

[8]  T. Yamamura,et al.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica , 2011, Proceedings of the National Academy of Sciences.

[9]  M. Mori,et al.  Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6 , 2010, Multiple sclerosis.